Objective: To examine the effect of letrozole on symptomatic leiomyomata.
Patients and Methods: In a prospective, intervention study , forty six premenopausal
women with fifty two leiomyomata were invited to take 5 mg letrozole daily for 3
treatment cycles of 28 days each. Leiomyoma, uterine and ovarian volumes, endometrial
thickness, gonadotrophins, and the scores of menstrual pictograms and Uterine Fibroid
Symptom and Health Related Quality of Life (UFS – HRQoL) were recorded at the start
and conclusion of this study.
Results: Letrozole resulted in 53.29% mean reduction in original leiomyomata volumes
(P < 0.01) without significant reduction in myoma free uterine tissue. Estradiol levels
dropped significantly from baseline levels (64.32 + 16.77) (mean + SD) to (40.83 +
12.032) pg/ml (p < 0.001) at the end of this study.
Conclusion: Adding to its significant shrinkage of leiomyomta, letrozole improved
leiomyoma related symptomology, quality of life
and menstrual pattern significantly.